Print Page      Close Window     

2019 News Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
01/17/19
Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
01/16/19
Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial